Last reviewed · How we verify

Miguel Santín — Portfolio Competitive Intelligence Brief

Miguel Santín pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Rifampicin plus Isoniazid Rifampicin plus Isoniazid marketed
Rifampicin alone Rifampicin alone marketed Rifamycin antibiotic Bacterial RNA polymerase β-subunit Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bausch Health Americas, Inc. · 1 shared drug class
  2. Institute of Tropical Medicine, Belgium · 1 shared drug class
  3. National Institute of Allergy and Infectious Diseases (NIAID) · 1 shared drug class
  4. National Taiwan University Hospital · 1 shared drug class
  5. Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji · 1 shared drug class
  6. Seoul National University Hospital · 1 shared drug class
  7. South China Children's Leukemia Group · 1 shared drug class
  8. Suzhou Zelgen Biopharmaceuticals Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Miguel Santín:

Cite this brief

Drug Landscape (2026). Miguel Santín — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/miguel-sant-n. Accessed 2026-05-16.

Related